Dr. Reddy's Laboratories, Incorporated

Other

Dr. Reddy's Research Foundation

Kareus Therapeutics, Sa

Venkateswarlu Akella

Subrahmanyam Duvvuri

Sriram K Rajagopal

Ranjan Chakrabarti

Braj Bhushan Lohray

Rajagopalan Ramanujam

Vidya Bhushan Lohray

Rao Bheema Paraselli

Ranga Madhavan Gurram

Shanavas Alikunju

Parimal Misra

Ajaya Kumar Reka

Ramesh Mullangi

Raju Sirisilla

Sharma Manohara Vedula

Uday Saxena

Srinivas Nanduri

Anji Reddy Kallam

Saibal Kumar Das

Sairam Pothukuchi

Vamsee Krishna Chintakunta

Sunilkumar Bhadramma Kochunarayana Pillai

Papi Reddy Purma

Rao Venkateswara Kalla

Srinivas Ssv Akella

Sastry V R S Thungathurthi

Shobha Madabhushi

Sharma Manohar Vedula

Ramachandra Puranik

Raghavendra Madhva Sattegeri

Archana Prabhakar Kulakarni

Novel small molecule compounds for reduction of A&#x3b2; 42 production and for treatment of Alzheimer's disease and other neurodegenerative disorders, methods of making them and pharmaceutical compositions containing them are described.

Compositions for reducing A&#x3b2; 42 production and their use in treating alzheimer's  disease (AD)

Novel small molecule compounds for reduction of A&#x3b2; 42 production and for treatment of Alzheimer's Disease and other neurodegenerative disorders, methods of making them and pharmaceutical compositions containing them are described.

Compositions for reducing a&#x3b2; 42 production and their use in treating alzheimer's disease (AD)

A 5(S)-(2'-hydroxyethoxy)-20(S)-camptothecin diasterisomer is described which is a better inhibitor of topoisomerase I than either the diastereoisomeric mixture 5(RS)-(2&#x2032;-hydroxyethoxy)-20(S)-camptothecin, or the 5(R)-(2&#x2032;-hydroxyethoxy)-20(S)-camptothecin diastereoisomer. Pharmaceutical compositions of the 5(S)-(2&#x2032;-hydroxyethoxy)-20(S)-camptothecin diastereoisomer are also described as are methods of using the compound for the inhibition of topoisomerase I and for the treatment of cancer.

5(S)-(2'-hydroxyethoxy)-20(S)-camptothecin and its preparation and use for the treatment of cancer

A crystalline form of 5(S)-(2'-hydroxyethoxy)-20(S)-camptothecin diastereoisomer of 5(RS)-(2&#x2032;-hydroxyethoxy)-20(S)-camptothecin is described that is characterized by having an X-ray powder diffraction pattern comprising one or more peak intensities expressed in degrees 2&#x3b8; that are selected from the group consisting of 7.2&#xb1;0.1, 9.4&#xb1;0.1, 11.02&#xb1;0.1, 12.00&#xb1;0.1, 14.54&#xb1;0.1, 15.2&#xb1;0.1, 18.92&#xb1;0.1, 21.86&#xb1;0.1, 22.74&#xb1;0.1 and 26.42&#xb1;0.1. Methods of making and using the compound are also described.

Crystalline form of 5(S)-(2-hydroxyethoxy)-20(S)-camptothecin

The present invention relates to novel antiobesity and hypocholesterolemic compounds, their derivatives, their analogs, their tautomeric forms, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates and pharmaceutically acceptable compositions containing them. More particularly, the present invention relates to novel &#x3b2;-aryl-&#x3b1;-oxysubstituted alkylcarboxylic acids of the general formula (I), their derivatives, their analogs, their tautomeric forms, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates and pharmaceutically acceptable compositions containing them. The present invention also relates to a process for the preparation of the above said novel compounds, their analogs, their derivatives, their tautomeric forms, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, pharmaceutically acceptable solvates and pharmaceutical compositions containing them. The present invention also relates to novel intermediates, processes for their preparation and their use in the preparation of compounds of formula (I).

Monocyclic compounds and their use in medicine: process for their preparation and pharmaceutical compositions containing them

The present invention relates to novel anticancer agents, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, and their pharmaceutically acceptable solvates. The present invention more particularly relates to novel derivatives of andrographolide, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, and their pharmaceutically acceptable solvates. The novel derivatives of andrographolide have the general formula (I).

Compounds having anticancer activity : process for their preparation and pharmaceutical compositions containing them

Anticancer compounds: process for their preparation and pharmaceutical compositions containing them

Fused 7-oxo-pyrimidinyl compounds, preparation, composition and use thereof

Novel water soluble C-ring analogues of 20(S)-camptothecin having the general formula 1.

Water soluble analogues of 20(S)-camptothecin

Novel water soluble C-ring analogues of 20(S)-camptothecin having the general formula 1,

Novel water soluble C-ring analogs of 20(S)-camptothecin having the formula 1. ##STR1## The compounds of the formula 1 are prepared from the compounds of the formula 12 having C-20(S) chiral carbon. The compounds of the formula 1 possess potent anti-cancer and anti-viral properties.

Water soluble C-ring analogues of 20(S)-camptothecin

Novel taxane derivatives and intermediates having the formula 1. ##STR1## and a process for the preparation of the compounds of the formula 1 from 14-.beta.-hydroxy-10-deacetylbaccatin III of formula 2 ##STR2## and pharmaceutically acceptable compositions containing the taxane derivatives and intermediates of formula 1.

Taxane derivatives from 14-.beta.-hydroxy-10 deacetylbaccatin III

Growing community of inventors

Hyderabad Telangana, India

Venkateswarlu Akella